Dr. Ebrahim S. Delpassand, MD

Dr. Delpassand practices at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas.

Dr. Delpassand's NPI, 1912923467, was assigned on July 15, 2006. Dr. Delpassand graduated from Tehran University of Medical Sciences School of Medicine in 1982. Dr. Delpassand holds Texas license H8621.

Dr. Delpassand's primary practice is Excel Diagnostics & Nuclear Oncology Center, at 9701 Richmond Ave Ste 122, Houston, TX 77042. The practice phone is (713) 781-6200.

Dr. Delpassand's primary practice is Excel Diagnostics & Nuclear Oncology Center in Houston, Texas. Dmand AI also links Dr. Delpassand to 1 physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Delpassand practices, 2 sites in all. Vendor and product names are available with a free account.

Nuclear radiology is Dr. Delpassand's primary specialty in the NPI Registry, under taxonomy code 2085N0904X. Dr. Delpassand is board certified in nuclear medicine by the American Board of Nuclear Medicine. Dmand AI has Dr. Delpassand's licenses on file in 2 states: Texas and Oklahoma.

CMS data shows 54 Medicare services from Dr. Delpassand across 2 procedure codes in 2024, all of them office visits, for 31 Medicare patients. Medicare paid $7,698 for them. Every service was in an office.

CMS counts 31 Medicare patients who saw Dr. Delpassand in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have high cholesterol, and 74% have high blood pressure. Their average risk score is 3.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Delpassand's median patient age at 77, with 50% women.

In 2024, Dr. Delpassand wrote 12 Medicare Part D claims. 100% of them were for generic drugs. They cover 1 drug, with $28 in total drug cost. In 2017, CMS named 22 claims across 2 drugs.

Dr. Delpassand accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 64 papers to Dr. Delpassand, published from 2005 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Radiopharmaceuticals, Neuroendocrine Tumors and Octreotide. Dr. Delpassand has published most often in J Nucl Med. Dr. Delpassand's most frequent co-authors are Jonathan R. Strosberg, MD, Edward M. Wolin, MD and Peeyush Bhargava, MD.

Dmand AI links Dr. Delpassand to 12 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Neuroendocrine Tumors, Neuroectodermal Tumors and Prostatic Neoplasms. Endocyte sponsors the most, 2.

CMS Open Payments shows 35 general payments to Dr. Delpassand from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Telix Pharmaceuticals paid the most, $7,442.

Dr. Delpassand graduated from Tehran University of Medical Sciences School of Medicine in 1982.

Dr. Delpassand is in network with 9 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.